Prolia - Home | Osteoporosis Treatment | Amgen

RELY ON PROLIA® AS PART OF A LONG-TERM TREATMENT STRATEGY TO HELP PROTECT PATIENTS FROM ONGOING RISK OF FRACTURES1–7

References:
  1. Cummings SR, et al. N Engl J Med. 2009;361:756–65.
  2. Kendler DL, et al. J Bone Miner Res. 2010;25:72–81.
  3. Miller PD, et al. J Clin Endocrinol Metab. 2016;101:3163–70.
  4. Recknor C, et al. Obstet Gynecol. 2013;121:1291–9.
  5. Roux C, et al. Bone. 2014;58:48–54.
  6. Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.
  7. Reid IR. Nat Rev Endocrinol. 2015;11:418–28.
  8. Ström O, et al. Arch Osteoporos. 2011;6:59–155.
  9. Baron R, et al. Bone. 2011;48:677–92.
  10. Prolia® (denosumab) Summary of Product Characteristics. Amgen. Last revised February 2020.
  11. Bolognese MA, et al. J Clinical Densitom. 2013;16:147–53.
  12. Khalid S, et al. Osteoporosis Int. 2017;28(Suppl 1):S64–5. Abstract presented at WCO-IOF-ESCEO 2017; OC21.
  13. Freemantle N, et al. Osteoporos Int. 2012;23:317–26.
  14. Karlsson L, et al. Osteoporos Int. 2015;26:2401–11.
  15. Durden E, et al. Arch Osteoporos. 2017;12:22–30.
  16. Reyes C, et al. Osteoporos Int. 2017;28:2297–3004.
  17. Hadji P, et al. Osteoporos Int. 2016;26:2967–78.

The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public